14C-XEN1101 not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101”In the company’s words, NCT04952467 on ClinicalTrials.gov
- Main trialPhase 1
- “This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of 14C-XEN1101 in healthy adult male subjects.”In the company’s words, NCT04952467 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 4 Oct 2021 | Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026